Abstract:Liquid biopsies are increasingly used for cancer molecular profiling that enables a precision oncology approach. Circulating extracellular nucleic acids (cell-free DNA; cfDNA), circulating tumor DNA (ctDNA), and circulating tumor cells (CTCs) can be isolated from the blood and other body fluids. This review will focus on current technologies and clinical applications for liquid biopsies. ctDNA/cfDNA has been isolated and analyzed using many techniques, e.g., droplet digital polymerase chain reaction, beads, emulsion, amplification, and magnetics (BEAMing), tagged-amplicon deep sequencing (TAm-Seq), cancer personalized profiling by deep sequencing (CAPP-Seq), whole genome bisulfite sequencing (WGBS-Seq), whole exome sequencing (WES), and whole genome sequencing (WGS). CTCs have been isolated using biomarker-based cell capture, and positive or negative enrichment based on biophysical and other properties. ctDNA/cfDNA and CTCs are being exploited in a variety of clinical applications: differentiating unique immune checkpoint blockade response patterns using serial samples; predicting immune checkpoint blockade response based on baseline liquid biopsy characteristics; predicting response and resistance to targeted therapy and chemotherapy as well as immunotherapy, including CAR-T cells, based on serial sampling; assessing shed DNA from multiple metastatic sites; assessing potentially actionable alterations; analyzing prognosis and tumor burden, including after surgery; interrogating difficult-to biopsy tumors; and detecting cancer at early stages. The latter can be limited by the small amounts of tumor-derived components shed into the circulation; furthermore, cfDNA assessment in all cancers can be confounded by clonal hematopoeisis of indeterminate potential, especially in the elderly. CTCs can be technically more difficult to isolate that cfDNA, but permit functional assays, as well as evaluation of CTC-derived DNA, RNA and proteins, including single-cell analysis. Blood biopsies are less invasive than tissue biopsies and hence amenable to serial collection, which can provide critical molecular information in real time. In conclusion, liquid biopsy is a powerful tool, and remarkable advances in this technology have impacted multiple aspects of precision oncology, from early diagnosis to management of refractory metastatic disease. Future research may focus on fluids beyond blood, such as ascites, effusions, urine, and cerebrospinal fluid, as well as methylation patterns and elements such as exosomes.

State-of-the-art Nanotechnologies for the Detection, Recovery, Analysis and Elimination of Liquid Biopsy Components in Cancer

Emerging Nanotechnologies for Liquid Biopsy: The Detection of Circulating Tumor Cells and Extracellular Vesicles

Nanotechnology for Detection of Circulating Tumor Cells and Extracellular Vesicles

Nanotechnology-Based Strategies for Early Cancer Diagnosis Using Circulating Tumor Cells as a Liquid Biopsy.

Blood-based Tumor Markers in Lung Cancer

Liquid biopsy for human cancer: cancer screening, monitoring, and treatment

Liquid biopsy: current technology and clinical applications

Liquid biopsies for cancer: From bench to clinic

Liquid biopsy for early diagnosis of non-small cell lung carcinoma: recent research and detection technologies

Advances In Analytic Nanotechniques For The Capture And Detection Of Circulating Tumor Cells

Recent Advances in Integrated Microfluidics for Liquid Biopsies and Future Directions.

Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments

Liquid biopsy: Circulating exosomal long noncoding RNAs in cancer

Liquid Biopsy in the Clinical Management of Cancers

Advances and Prospects in Liquid Biopsy Techniques for Malignant Tumor Diagnosis and Surveillance

Recent advances in droplet‐based microfluidics in liquid biopsy for cancer diagnosis

Beyond blood: Advancing the frontiers of liquid biopsy in oncology and personalized medicine

Liquid biopsy in cancer current: status, challenges and future prospects

LIQUID BIOPSY: A NON-INVASIVE TOOL TO DETECT CANCER AT AN EARLY STAGE

Advances in early detection methods for solid tumors

Liquid biopsy: paving a new avenue for cancer research